|
|
|
Insider
Information: |
Falberg Kathryn E |
Relationship: |
Director |
City: |
Rockville |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
12 |
|
Direct
Shares |
909,461 |
|
Indirect Shares
|
402,106 |
|
|
Direct
Value |
$54,281,447 |
|
|
Indirect Value
|
$8,988,449 |
|
|
Total
Shares |
1,311,567 |
|
|
Total
Value |
$63,269,895 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
2
|
Stock
price went up :
|
1
|
1
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
Percentage
Gain/Loss : |
48.2%
|
-76.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Halozyme Therapeutics Inc |
HALO |
Director |
2016-05-04 |
358,253 |
2007-05-15 |
0 |
Premium* |
|
Nuvelo Inc |
ABIO |
CFO and COO |
2009-06-16 |
0 |
|
0 |
Premium* |
|
Jazz Pharmaceuticals Inc |
JAZZ |
EVP and CFO |
2014-03-05 |
133,387 |
2012-08-16 |
0 |
Premium* |
|
Medivation Inc |
MDVN |
Director |
2016-09-28 |
0 |
2016-09-28 |
0 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Director |
2015-05-06 |
12,572 |
|
0 |
Premium* |
|
Aimmune Therapeutics, Inc. |
AIMT |
Director |
2020-10-13 |
0 |
2020-10-10 |
0 |
Premium* |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2016-07-15 |
2,640 |
2016-07-15 |
0 |
Premium* |
|
Trade Desk, Inc. |
TTD |
Director |
2024-03-08 |
242,609 |
2024-03-08 |
50,000 |
Premium* |
|
Sio Gene Therapies Inc |
SIOX |
Director |
2017-04-17 |
53,937 |
2017-04-17 |
0 |
Premium* |
|
Arcus Biosciences Inc |
RCUS |
Director |
2023-06-15 |
46,900 |
2023-06-15 |
102,106 |
Premium* |
|
Tricida, Inc. |
TCDA |
Director |
2021-06-10 |
59,163 |
2018-07-02 |
0 |
Premium* |
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2022-11-30 |
0 |
2022-12-05 |
250,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-11 |
4 |
OE |
$7.35 |
$2,079,163 |
D/D |
141,830 |
87,282 |
0 |
- |
|
TTD |
Trade Desk, Inc. |
Director |
|
2024-03-08 |
4 |
OE |
$1.80 |
$185,763 |
D/D |
103,030 |
345,639 |
0 |
- |
|
TTD |
Trade Desk, Inc. |
Director |
|
2024-03-08 |
4 |
S |
$81.90 |
$8,438,201 |
D/D |
(103,030) |
242,609 |
0 |
% |
|
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-11 |
4 |
D |
$48.60 |
$4,230,970 |
D/D |
(87,057) |
58,201 |
0 |
- |
|
NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
|
2022-12-01 |
4 |
B |
$1.97 |
$167,599 |
I/I |
84,959 |
160,000 |
2.1 |
- |
|
NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
|
2022-11-30 |
4 |
B |
$1.85 |
$139,088 |
I/I |
75,041 |
75,041 |
2.1 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2018-11-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
69,894 |
58,750 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2018-11-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
69,894 |
69,894 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-10-10 |
4 |
D |
$34.50 |
$2,411,343 |
I/I |
(69,894) |
0 |
0 |
- |
|
AIMT |
Aimmune Therapeutics, Inc... |
Director |
|
2020-10-10 |
4 |
D |
$34.50 |
$2,249,124 |
D/D |
(65,192) |
0 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
58,201 |
58,201 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,201) |
0 |
0 |
- |
|
SIOX |
Sio Gene Therapies Inc |
Director |
|
2017-04-17 |
4 |
B |
$18.54 |
$999,992 |
D/D |
53,937 |
53,937 |
2.39 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-18 |
4 |
A |
$0.00 |
$0 |
I/I |
53,000 |
53,000 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
SVP and CFO |
|
2012-01-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(53,000) |
0 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP and CFO |
|
2012-08-16 |
4 |
S |
$47.57 |
$2,521,210 |
I/I |
(53,000) |
0 |
0 |
- |
|
RCUS |
Arcus Biosciences Inc |
Director |
|
2023-06-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
50,504 |
40,100 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
Director |
|
2012-11-13 |
4 |
B |
$5.21 |
$260,500 |
D/D |
50,000 |
160,000 |
2.39 |
- |
|
HALO |
Halozyme Therapeutics Inc |
Director |
|
2013-08-12 |
4 |
B |
$6.72 |
$335,935 |
D/D |
50,000 |
230,000 |
2.39 |
- |
|
HALO |
Halozyme Therapeutics Inc |
Director |
|
2013-08-14 |
4 |
B |
$6.91 |
$345,710 |
D/D |
50,000 |
280,000 |
2.39 |
- |
|
MDVN |
Medivation Inc |
Director |
|
2016-09-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(50,000) |
0 |
0 |
- |
|
NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
|
2022-12-02 |
4 |
B |
$1.98 |
$93,187 |
I/I |
47,000 |
207,000 |
2.1 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP and CFO |
|
2013-03-05 |
4 |
OE |
$7.35 |
$324,988 |
D/D |
44,216 |
133,417 |
0 |
- |
|
NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
|
2022-12-05 |
4 |
B |
$1.95 |
$83,962 |
I/I |
43,000 |
250,000 |
2.1 |
- |
|
TTD |
Trade Desk, Inc. |
Director |
|
2016-11-14 |
4 |
B |
$25.99 |
$1,039,600 |
I/I |
40,000 |
40,000 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|